Buffalo Translational Consortium News
Common insecticides mimic melatonin, creating higher potential risk for diabetes and metabolic diseases
Old suspects find new mechanisms to alter human health
Insecticide compounds implicated in circadian activity disruption
Disruptions in human circadian rhythms are known to put people at higher risk for diabetes and other metabolic diseases but the mechanism involved is not well-understood.
Directions for future research
Role of the Drug Development Core in the UB Clinical and Translational Science Institute
The main objective of the University at Buffalo Clinical and Translational Science Institute (CTSI) Drug Development core is to foster innovation in drug development and clinical therapeutics research. While providing expert mentoring for researchers from the Buffalo Translational Consortium, the core also collaborates with industry partners, arranges access to CTSI core laboratory facilities that specialize in drug development, and helps investigators to prepare a top-flight grant application or cutting-edge research protocol.
Drug Development Core Director Gene D. Morse, PharmD, FCCP, BCPS, SUNY Distinguished Professor in the UB School of Pharmacy and Pharmaceutical Sciences Department of Pharmacy Practice, will present an overview outlining some of the services and resources the core provides to investigators on Wednesday, February 22, 12 - 1 p.m., in 339 Cary Hall, South Campus, UB.
UB-led consortium that earned prestigious National Institutes of Health grant moves into a new phase
In August of 2015, a University at Buffalo-led consortium of Western New York academic, health care and research institutions and community partners won a prestigious $15 million award from the National Institutes of Health to help expedite the translation of basic biomedical research in the region into practical health care benefits for the community.
As of February 2017, that entity will be known as the University at Buffalo Clinical and Translational Science Institute (CTSI).
The new identity was first revealed in a profile of the CTSI published by The Buffalo News on January 29. It was formally introduced to the UB community during the 2017 State of the School address delivered by Vice President for Health Sciences and Dean of the Jacobs School of Medicine and Biomedical Sciences Michael E. Cain, MD, and in a story that ran in UBNow, the home of campus news for the university.
The adoption of the new name and visual identity is intended to represent the collaborative and scientific mission of the institute. The CTSI’s new logo features the UB logo and is consistent with the new brand and identity strategy launched by the university in 2016. The announcement is coupled with the launch of the @BuffaloCTSI Twitter account, which will provide updates on developments at the CTSI and in translational science generally.
“The change in our name to the Clinical and Translational Science Institute is a better reflection of the innovative clinical and translational work we are engaged in,” said Timothy F. Murphy, MD, SUNY Distinguished Professor in the UB Department of Medicine, senior associate dean for translational research in the Jacobs School of Medicine and Biomedical Sciences, and the institute’s director. “It is intensely focused on groundbreaking research, new discoveries and providing patients with access to innovative, new treatments and therapies.”
The tagline for the CTSI is: Advancing research discoveries to improve health for all. “This statement fully reflects the CTSI mission,” said Murphy. “There have been unprecedented advances in medical research in the last few decades, but it takes too long to translate those discoveries into tangible health benefits. The Buffalo CTSI embodies a regional commitment to maximizing the return on our area’s investment in medical research, based on the principle that the best health care goes hand in hand with the best science.”
Reproducible research, in which statistical programming and documentation is sufficient so that others may replicate results and the research process, is gaining widespread practice in biostatistics and many other areas of science. Biostatisticians have a responsibility to implement reproducible research, yet there are many challenges to doing so in a collaborative research environment within an academic medical center.
Popular tools for reproducible research, such as knitR and R Markdown, rely on plain text editors for document preparation. Despite the merits of these programs, Microsoft Word remains the mainstay, and sometimes singular option, for manuscript preparation in academic medicine. To our knowledge, there are no broadly accessible tools to integrate document preparation in Word with statistical code, results and data.
With this need in mind, we developed StatTag (stattag.org), a free plug-in for conducting reproducible research using Microsoft Word and Stata, SAS or R. StatTag provides an interface to edit statistical code directly from Word and allows users to embed statistical output from that code (estimates, tables, figures) within Word.
This talk will present: 1) an overview of reproducible research and the challenges specific to biostatistics units within clinical and translational science; 2) an introduction to StatTag, including worked examples; and 3) future work to promote the widespread adoption of reproducible research within the academic medical community.
Learn more at a lecture sponsored by UB's Clinical and Translational Science Institute BERD (Biostatisitics, Epidemiology and Research Design) core and the School of Public Health and Health Professions Department of Biostatistics:
StatTag: A Reproducible Research Tool for Clinical and Translational Science
Leah J. Welty, PhD
Associate Professor of Preventive Medicine (Biostatistics) and Psychiatry and Behavior Sciences
Northwest University Freiburg School of Medicine
Thursday, February 9
125 Kimball Tower
UB South Campus
This is a general audience talk.